Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Kairos Pharma, LTD. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 14 | 14 | 0 |
| Shares | 445.0K | 855.7K | +410.7K (+92.3%) |
| Value | $505.8K | $607.5K | +$101.6K (+20.1%) |
New holders (5)
Institutions that held Kairos Pharma, LTD. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 321,738 | $228.4K | 0.00% |
| HRT Financial LP | 21,319 | $15.0K | 0.00% |
| Virtu Financial LLC | 20,278 | $14.0K | 0.00% |
| Two Sigma Advisers, LP | 15,142 | $10.8K | 0.00% |
| Advisor Group Holdings, Inc. | 13,045 | $9.26K | 0.00% |
Sold out (5)
Institutions that held Kairos Pharma, LTD. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Two Sigma Securities, LLC | 24,895 | $29.1K |
| FNY Investment Advisers, LLC | 23,500 | $27.0K |
| Quadrature Capital Ltd | 14,887 | $17.4K |
| UBS Group AG | 5,979 | $7.00K |
| Royal Bank of Canada | 1,000 | $1.00K |